MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest growing drug classes in human healthcare. Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. Over therapeutic antibody programs based on the company s technologies are currently in development, of which are in clinical trials. The company s most advanced proprietary program is MOR , a first in class antibody against GM CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR is part of MorphoSys s collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR and MOR , both for the treatment of cancer. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Quote | MorphoSys AG (NASDAQ:MOR)
Last: | $18.185 |
---|---|
Change Percent: | 0.47% |
Open: | $18.08 |
Close: | $18.10 |
High: | $18.22 |
Low: | $18.08 |
Volume: | 44,453 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | MorphoSys AG (NASDAQ:MOR)
2024-06-20 04:02:15 ET More on MorphoSys, Novartis, etc. Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript) Novartis: Buy This Blue-Chip Dividend Stock On Sale Now MorphoSys: Hold Rating Until The Novartis Deal Closes Novartis, Roche facing...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
Message Board Posts | MorphoSys AG (NASDAQ:MOR)
Subject | By | Source | When |
---|---|---|---|
News: $MOR MorphoSys Announces That Its Patents Were | whytestocks | investorshub | 01/26/2019 7:46:16 PM |
Molycor Adds Magnesium Product Specialist To Advisory Committee | abriana90 | investorshub | 01/17/2012 1:32:48 PM |
Molycor Adds Power Consultant To Advisory Committee | abriana90 | investorshub | 01/11/2012 1:54:22 PM |
New web site up and running Looks Great | abriana90 | investorshub | 12/21/2011 3:11:49 PM |
Did you set up this board with the | CleanForMePlease | investorshub | 12/10/2011 3:57:44 AM |
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...
2024-06-15 22:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...